The change in Ki67 levels as a result of short-term treatment with endocrine treatment is an attractive end-point for assessing the biological responsiveness of primary tumours to a given therapy and has been shown to be related to the reduction in risk of recurrence from those treatments [10]. The gene discussed is MKI67; the disease is neoplasm.